Compare Dr. Reddys with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ASTRAZENECA PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ASTRAZENECA PHARMA DR. REDDYS LAB/
ASTRAZENECA PHARMA
 
P/E (TTM) x 16.8 94.2 17.9% View Chart
P/BV x 3.2 26.5 12.2% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DR. REDDYS LAB   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
ASTRAZENECA PHARMA
Mar-18
DR. REDDYS LAB/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,8751,278 225.0%   
Low Rs1,888883 213.9%   
Sales per share (Unadj.) Rs930.2228.4 407.3%  
Earnings per share (Unadj.) Rs117.410.4 1,133.0%  
Cash flow per share (Unadj.) Rs185.816.3 1,142.4%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.498.8 854.9%  
Shares outstanding (eoy) m166.0725.00 664.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.7 54.1%   
Avg P/E ratio x20.3104.2 19.5%  
P/CF ratio (eoy) x12.866.4 19.3%  
Price / Book Value ratio x2.810.9 25.8%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,49627,008 1,464.4%   
No. of employees `00022.01.4 1,619.9%   
Total wages/salary Rs m33,5621,535 2,186.0%   
Avg. sales/employee Rs Th7,032.84,210.9 167.0%   
Avg. wages/employee Rs Th1,527.91,132.2 134.9%   
Avg. net profit/employee Rs Th887.7191.1 464.6%   
INCOME DATA
Net Sales Rs m154,4825,710 2,705.5%  
Other income Rs m3,375123 2,755.1%   
Total revenues Rs m157,8575,833 2,706.5%   
Gross profit Rs m31,782463 6,865.8%  
Depreciation Rs m11,348147 7,698.8%   
Interest Rs m8890-   
Profit before tax Rs m22,920438 5,232.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,858179 2,156.5%   
Profit after tax Rs m19,500259 7,526.1%  
Gross profit margin %20.68.1 253.8%  
Effective tax rate %16.840.8 41.2%   
Net profit margin %12.64.5 278.2%  
BALANCE SHEET DATA
Current assets Rs m111,1013,209 3,462.0%   
Current liabilities Rs m58,9732,070 2,849.6%   
Net working cap to sales %33.720.0 169.1%  
Current ratio x1.91.6 121.5%  
Inventory Days Days7972 109.7%  
Debtors Days Days9435 269.8%  
Net fixed assets Rs m101,245790 12,811.0%   
Share capital Rs m83050 1,660.0%   
"Free" reserves Rs m139,4062,419 5,762.2%   
Net worth Rs m140,2362,469 5,679.2%   
Long term debt Rs m22,0000-   
Total assets Rs m224,6564,605 4,878.1%  
Interest coverage x26.8NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.71.2 55.5%   
Return on assets %9.15.6 161.3%  
Return on equity %13.910.5 132.5%  
Return on capital %14.917.7 84.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,673300 29,602.1%   
Fx outflow Rs m19,1042,015 948.1%   
Net fx Rs m69,569-1,715 -4,055.7%   
CASH FLOW
From Operations Rs m28,70488 32,655.3%  
From Investments Rs m-7,727-94 8,255.3%  
From Financial Activity Rs m-21,326NA-  
Net Cashflow Rs m-314-6 5,508.8%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.4 0.3 1,800.0%  
FIIs % 35.3 15.7 224.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 9.1 168.1%  
Shareholders   75,885 12,856 590.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 15, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS